Update: New focus with new data awaited
Management has indicated that the C-Cure cardiac regeneration project (Phase III data in mid-2016) might be fully partnered from 2017. This will enable the main focus to move onto Chimeric Antigen Receptor (CAR) T-cell cancer therapies and the associated allogeneic development. The new indicative value of €88/$95 per share is an interim assessment while Phase III CHART-1 C-Cure data, due mid-2016, is awaited and before the Phase I CAR T-cell study completes. C-Cure partnering is not expected till 2017. Edison estimates that 2015 year-end cash was about €107m.Celyad is engaged in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Co. provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. Co.'s main product is C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy. Co.'s drug product candidates are autologous cell therapy treatments. In autologous procedures, a patient's cells are harvested, selected, reprogrammed and expanded, and then infused back into the same patient.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.